Started my first patient on colchicine She is an ideal candidate: 69 yo female with non-obstructive LAD lesion with CPPD athropathy, LDL-C 53 HDL-C 92 but CRP 7 on a statin. Also scheduled a CLEERLY to monitor plaque changes over time. Still waiting for Ziltivekimab!

I have never before tweeted anything political but I am outraged by the the many college student groups ( for example 30 at Harvard) that support Hamas in their murder of over 1200 Israelis. As a biotech CEO, I pledge to never hire a person who supports Hamas. Anti-semitism

The Moral Deficiencies of a Liberal Education nytimes.com/2023/10/17/opi… An articulate article by bioethicist Zeke Emanuel regarding the moral blindness of the student groups that justified the Hamas terrorist massacre. We need to educate but also hold these students accountable.

In today's clinic, 52 yo with premature ASCVD with FH and very high Lp(a) controlled on Repatha and statin. He has two sons, oldest age 18 has LDL-C 60mg/dl and Lp(a) 84 nmol/L, the other age 12 with LDL-C of 124 mg/dl and Lp(a) 400 nmol/L. I started rosuvastatin 5 mg of the

Patient will turn 100 in a few weeks. She has genetically confirmed FH and no clinical ASCVD. My search for resilience genes such as Klotho, IL-6, ACE, CETP or FOXO3 have not panned out. Other suggestions for protective genes?

48 yo male presents with LDL > 350mg/dl and Xanthelesmas. His "FH was cured after stopping the Carnivore diet and xanthelesmas are resolving. Now on a statin due to CAC score of 355. We need to warn people about the potential harm of the carnivore diet.

My biotech TV interview about the history of New Amsterdam Pharma and Obicetrapib eur01.safelinks.protection.outlook.com/?url=https%3A%…

podcasters.spotify.com/pod/show/ellio… Listen to a incredible podcast of my primary care physician brother, Elliott interviewing my son, Preventive Cardiologist David. I am a very proud brother and father

We’ve met the enrollment target in our pivotal Phase 3 PREVAIL CVOT and, driven by strong interest globally, expect to randomize more than 9,000 patients with a history of ASCVD. bit.ly/3TTqpAs

LDL-p vs ApoB. Both outperform LDL-c and perhaps non-HDL-c in risk assessment especially on statins. Although, I am big fan of ApoB, I often prefer LDL-p because discordance from LDL-c is more evident. This is a good example in a patient with premature ASCVD on a statin.

Thanks for all the feedback. Yes insulin resistance (IR) is the main driver behind LDL-c vs LDL-p discordance but also apoB vs LDL-p discordance ( see attached by the iconic Tom Dayspring)In the setting of IR, I recommend low carb diets. Keto may work but in susceptible patients

As a medical school professor, I spoke yesterday at a #upenn session with President, Provost and others. Here is what I said, a plea to American academia on behalf of Jewish students, staff and faculty. #israel #HateSpeech #Zionism #AcademicTwitter

We’re excited to kick off our R&D Day event this morning. Investors are invited to join our live webcast to learn more about our science and commercialization plans, and to hear cardiologists discuss how new oral lipid-lowering therapies could change patient care.

Two conferences, two continents, one growing team and one goal: To share new research on our investigational CETP inhibitor. Thank you to everyone at #NLASessions for another outstanding lipid-focused event.

The Prevention World lost a giant. George Bakris was the most prolific researcher, teacher and clinician in the history of hypertension. He will live on through his great work. I will remember him most as a great friend and colleague who was always eager to help with his amazing

My first patient with serial CLEERLYs following two years of Repatha. With excellent control of LDL-C and a reduction in Lp(a) there is a marked decrease in non-calcified plaque volume and an increase in calcified plaque. The patient is happy and so is his interventional

Thank you to the hundreds of patients and investigators across ten countries who participated in our Phase 3 BROOKLYN trial. Your support moves us closer to our goal of helping people at risk for cardiovascular disease. bit.ly/4fk9iSn

Before and after xanthoma regression in a patient with the Lebanese FH mutation. Interventional lipidology works much better than plastic surgery.

nytimes.com/2023/07/27/hea… This is the obituary in the NYT of the 117 year old women with the loss of function CETP variant identified in the Bronx Aging Study